Respiratory medicine
Can blocking IgE-making B cells prevent asthma attacks?
Open access · cc by · source: Europe PMC
Quilizumab, an antibody that targets the B cells that make IgE, lowered IgE levels by about a third but did not reduce asthma attacks or improve breathing in adults with hard-to-control allergic asthma.
Study at a glance
- Design
- RCT — Phase II, multinational, double-blind, placebo-controlled RCT; three quilizumab dosing regimens vs placebo (1:1:1:1) for 36 weeks plus 48 weeks of follow-up
- N
- N=578 · 578 adults randomised across four arms (433 quilizumab, 145 placebo)
- Population
- Adults aged 18-75 with allergic asthma uncontrolled despite high-dose inhaled corticosteroids plus a second controller, with at least one recent exacerbation, at sites in 14 countries
- Outcome
- Primary: annualised rate of asthma exacerbations to week 36; secondary: FEV1, symptom scores, rescue inhaler use, night awakenings; also IgE levels, biomarker subgroups and safety
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Quilizumab was well tolerated and clearly active biologically, cutting total and allergen-specific IgE by 30-40% at week 36 in every dose group. However, exacerbation rates did not fall meaningfully: the best arm (300 mg monthly) showed a non-significant 19.6% reduction, and the other two arms had slightly more exacerbations than placebo. Lung function, symptoms, rescue-inhaler use and quality of life did not improve, and no biomarker subgroup showed a consistent benefit; the sponsor stopped the trial early for lack of efficacy.
Methodology
Adults whose allergic asthma stayed uncontrolled despite high-dose inhaled steroids and a second controller were randomly assigned to one of three under-the-skin quilizumab schedules (300 mg monthly, or 150 mg or 450 mg quarterly) or placebo for 36 weeks, with patients and site staff blinded. The main outcome was the yearly rate of exacerbations needing systemic steroids or hospital care; lung function, diary symptoms and quality of life were secondary. The researchers also tested whether type 2 biomarkers (periostin, blood eosinophils, exhaled nitric oxide, IgE) picked out patients who benefited more.
Limitations
The trial tested only 36 weeks of treatment in severe, uncontrolled allergic asthma, so the authors cannot say whether longer treatment or another subgroup would respond. They could not directly measure the target cells in patients, so depletion of IgE-producing B cells is inferred from falling IgE rather than shown. It was a Phase II study funded and largely authored by the manufacturer, used 90% confidence intervals and a lenient alpha typical of early-phase trials, and the earlier allergen-challenge studies that looked promising were in mild asthma, a different population.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
A drug can move a biomarker without helping patients.
Hitting a biological target did not translate into clinical benefit in a phase II RCT: quilizumab lowered IgE by 30-40% in severe uncontrolled allergic asthma but did not meaningfully reduce exacerbations (best arm a non-significant 19.6% reduction) or improve lung function, and the trial was stopped for lack of efficacy.
Evidence for the claim as stated.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Biologic trials in this set were run in different asthma populations: MEDI-528 in mild asthma showed early hints of benefit on exercise challenge, while quilizumab in severe uncontrolled allergic asthma failed, and its own earlier promising allergen-challenge studies had been in mild asthma. Different drugs, targets and severities mean this is a limit on generalising from mild to severe disease rather than a direct conflict.
Related papers in this topic
Same topic cluster — not a recommendation engine.